Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Background Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world‐wide. Three‐quarters of women present when the disease has spread throughout the abdomen (stage III or IV) and treatment consists of a combination of debulking surgery and platinum‐based chemotherapy. Although initial responses to chemotherapy are good, most women will relapse and require further chemotherapy and will eventually...